CN105748619A - Pharmaceutical composition for treating plasma cell mastitis and preparation method thereof - Google Patents
Pharmaceutical composition for treating plasma cell mastitis and preparation method thereof Download PDFInfo
- Publication number
- CN105748619A CN105748619A CN201610187150.7A CN201610187150A CN105748619A CN 105748619 A CN105748619 A CN 105748619A CN 201610187150 A CN201610187150 A CN 201610187150A CN 105748619 A CN105748619 A CN 105748619A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- pharmaceutical composition
- fruit
- medicine material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 70
- 206010066170 Plasma cell mastitis Diseases 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 76
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 60
- 244000268590 Euryale ferox Species 0.000 claims abstract description 34
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 33
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 33
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims description 47
- 240000008488 Thlaspi arvense Species 0.000 claims description 32
- 235000008214 Thlaspi arvense Nutrition 0.000 claims description 32
- 235000005412 red sage Nutrition 0.000 claims description 32
- 241000576429 Forsythia suspensa Species 0.000 claims description 31
- 239000009636 Huang Qi Substances 0.000 claims description 31
- 239000002775 capsule Substances 0.000 claims description 31
- 235000006487 Euryale ferox Nutrition 0.000 claims description 30
- 235000008113 selfheal Nutrition 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000000694 effects Effects 0.000 abstract description 31
- 210000000952 spleen Anatomy 0.000 abstract description 14
- 210000003734 kidney Anatomy 0.000 abstract description 12
- 230000035876 healing Effects 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 206010007247 Carbuncle Diseases 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 241000931143 Gleditsia sinensis Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000005272 common selfheal Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 201000010099 disease Diseases 0.000 description 21
- 208000025865 Ulcer Diseases 0.000 description 17
- 206010061926 Purulence Diseases 0.000 description 16
- 230000036269 ulceration Effects 0.000 description 16
- 230000006378 damage Effects 0.000 description 8
- 208000004396 mastitis Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000009835 boiling Methods 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000003890 fistula Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010016717 Fistula Diseases 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010067143 Fistula discharge Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 244000148137 Patrinia villosa Species 0.000 description 1
- 235000019109 Patrinia villosa Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating plasma cell mastitis and a preparation method thereof.The pharmaceutical composition is a medicament prepared from traditional Chinese medicine raw materials by weight.The traditional Chinese medicine raw materials comprise, by weight, 9-10 parts of Chinese thorowax roots, 10-15 parts of cortex moutan, 9-10 parts of Chinese honeylocust spines, 10-20 parts of herba patriniae, 10-20 parts of fructus forsythiae, 25-35 parts of raw milkvetch roots, 5-15 parts of glossy privet fruit, 9-30 parts of common selfheal fruit-spike, 5-15 parts of fructus liquidambaris, 10-20 parts of roots of red-rooted salvia, 10-20 parts of cornu cervi degelatinatum and 10-20 parts of gorgon euryale seeds.The pharmaceutical composition has the effects of invigorating the spleen, tonifying the kidney, dredging collaterals, eliminating carbuncle and removing stasis, the effects of promoting pus generation for patients in the non-pus period, promoting rupture for patients in the pus period and promoting healing for patients in the rupture period, and the life quality of the patients is improved fundamentally; in addition, the pharmaceutical composition is free of obvious toxic and side effects.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly it relates to an be used for treating thick liquid cell
Pharmaceutical composition of property mastitis and preparation method thereof.
Background technology
Plasma cell mastitis (being also called duct ectasia) is cured the desease and belongs to acne acute mastitis category.The traditional Chinese medical science
Think that this disease is many by caused by inadequate natural endowment, inernal injuries caused by seven emotions, Chong and Ren channel disorder, diseases caused by external factors perverse trend." woman's breast belongs to
Stomach, nipple belongs to liver ", this disease and liver stomach two are through in close relations.Congenital kidney essence deficiency, causes crater nipple
It is this void Deng micromazia disease；Feelings will is not smooth, and liver dysfunction causes the transportation capabilities of spleen to be lacked of proper care,
Retention of water-damp in the body, makes wet one-tenth phlegm, stagnation of QI due to depression of the liver, and ying blood from, qi depression to blood stasis, is not agglomerated into block, Yu Jiuhua
Heat, combination of phlegm and heat is real for mark；It is rotten that heat contains meat, and meat corruption becomes purulence, and fistulization after bursting, simulataneous insufficiency and excessive is sent out as this disease.
Sick position is at breast, relevant to liver, spleen, stomach, kidney.
The symptom feature of plasma cell mastitis meets Ming Dynasty's Chen Shigong at " the cloudy half light of surgery orthodox school ulcer half
Disease song the 5th " in description, " disease of negative and positive two is intersected, and life and death can be recruited with thing of holding concurrently, and low-grade fever is slightly cold micro-red swollen,
Half is confused the most refreshing the most flat high.Though it is how unable that arteries and veins carrys out number, though diet meal does not disappears, swell and do not burst because spleen is weak, burst
And do not hold back and have mercy on into purulence ".This piece points out again " swell and do not burst because spleen is weak ... it is the most adjustable that the moon transfers sun to ", clearly carries
Go out sore to swell and do not burst insufficiency of the spleen because of it, burst and do not hold back because its purulence is many not to the utmost.The spy of plasma cell mastitis
Point be breast with lump or with redness, disunion for a long time after postoperative or ulceration, formed fistula or abscess
Discharge the cleanest through ulceration but fester.In general, plasma cell mastitis had both had and had been difficult to into purulence, after becoming purulence
Purulence goes out insufficiency of the spleen performances such as the most smooth, it may have the yang syndrome performances such as red, swollen, hot, pain, and patient's purulence goes out not
Freely also causing disorder of qi relevant with deficiency of kidney-QI, Chong and Ren channel disorder, therefore, the dialectical deficiency of spleen and stomach that meets is held concurrently
There are the simulataneous insufficiency and excessive of heat poison, half cloudy half yang syndrome.
Plasma cell mastitis patient mostly is the women of child-bearing age, can behave as red swelling of the skin, lump border in early days
Clear, skin temperature rise, subareolar abscess, can feed through to major part breast, later stage abscess can spontaneous ulceration,
Protracted course of disease, forms fistula or sinus.At present, the treatment of plasma cell mastitis with anti-infective therapy,
Hormone therapy, operation or drainage are changed dressings as main method, and Chinese medicine is mainly used in making pathology limitation or promoting
The arrival on incision opportunity.
But, there are the following problems to use current methods for the treatment of meeting:
Anti-infective therapy's method is unsatisfactory for the disease damage effect not having concurrent infection；
Though methods of hormonal treatment short-term is effective, but there is side effect in long-term extensive application, and is not for disease
Cause, it is easy to repeatedly, even if sewing up after debridement, the most still has quite a few patient can not first intention；
Perform the operation or drainage dressing change method exists otch delayed union, do not close up in ulceration sore face, medical expense
The problems such as costliness, more importantly, the misery performed the operation and change dressings and postoperative mammary contour change patient
Psychology cause certain negative effect.Plasma cell mastitis is a kind of benign disease, and patient age
Many below 40 years old, should reduce the operation wound of patient as far as possible, be conduit because of the pathological characteristic of this disease again
Caused by interior a large amount of abnormal secretions, it is thorough that operation is difficult to excision, and dressing change also is difficult to drainage and puts in place, so
Do not advocate local is taked the most positive operation method.
Therefore, plasma cell mastitis belongs to the difficult diseases in mammary gland disease, and in prior art also
There is no effective treatment means.
Summary of the invention
It is an object of the present invention to provide a kind of Chinese medicine material group for treating plasma cell mastitis
Compound, pharmaceutical composition and application and for treating the preparation of pharmaceutical composition of plasma cell mastitis
Method.
Further object is that provide a kind of safely and effectively and non-evident effect for treating
Pharmaceutical composition of plasma cell mastitis and preparation method thereof.
According to an aspect of the present invention, it is provided that a kind of Chinese medicine material group for treating plasma cell mastitis
Compound, described Chinese medicine material composition includes by weight: radix bupleuri 9 parts-10 parts, moutan bark 10 part-15
Part, spina gleditsiae 9 parts-10 parts, field pennycress 10 parts-20 parts, the capsule of weeping forsythia 10 parts-20 parts, the raw Radix Astragali 25 parts
-35 parts, the fruit of glossy privet 5 parts-15 parts, selfheal 9 parts-30 parts, play both sides of the street 5 parts-15 parts, the red sage root 10
Part-20 parts, cornu cerve degelatinatum 10 parts-20 parts and Gorgon fruit 10 parts-20 parts.
According to the exemplary embodiment of the present invention, Chinese medicine material composition may include that radix bupleuri by weight
10 parts, moutan bark 10 parts, spina gleditsiae 10 parts, field pennycress 15 parts, the capsule of weeping forsythia 15 parts, the raw Radix Astragali 30
Part, the fruit of glossy privet 10 parts, selfheal 20 parts, play both sides of the street 15 parts, the red sage root 15 parts, cornu cerve degelatinatum 15 parts and
Gorgon fruit 15 parts.
According to the exemplary embodiment of the present invention, Chinese medicine material composition may include that radix bupleuri by weight
10 parts, moutan bark 12 parts, spina gleditsiae 10 parts, field pennycress 15 parts, the capsule of weeping forsythia 15 parts, the raw Radix Astragali 30
Part, the fruit of glossy privet 10 parts, selfheal 30 parts, play both sides of the street 15 parts, the red sage root 15 parts, cornu cerve degelatinatum 15 parts and
Gorgon fruit 15 parts.
According to a further aspect in the invention, it is provided that a kind of drug regimen for treating plasma cell mastitis
Thing, the medicament that this pharmaceutical composition is made up of Chinese medicine material, Chinese medicine material includes by weight: radix bupleuri
9 parts-10 parts, moutan bark 10 parts-15 parts, spina gleditsiae 9 parts-10 parts, field pennycress 10 parts-20 parts, even
Stick up 10 parts-20 parts, the raw Radix Astragali 25 parts-35 parts, the fruit of glossy privet 5 parts-15 parts, selfheal 9 parts-30 parts,
Play both sides of the street 5 parts-15 parts, the red sage root 10 parts-20 parts, cornu cerve degelatinatum 10 parts-20 parts and Gorgon fruit 10 parts-20 parts.
According to the exemplary embodiment of the present invention, Chinese medicine material may include that by weight radix bupleuri 10 parts,
Moutan bark 10 parts, spina gleditsiae 10 parts, field pennycress 15 parts, the capsule of weeping forsythia 15 parts, the raw Radix Astragali 30 parts, glossy privet
Son 10 parts, selfheal 20 parts, play both sides of the street 15 parts, the red sage root 15 parts, cornu cerve degelatinatum 15 parts and Gorgon fruit 15
Part.
According to the exemplary embodiment of the present invention, Chinese medicine material may include that by weight radix bupleuri 10 parts,
Moutan bark 12 parts, spina gleditsiae 10 parts, field pennycress 15 parts, the capsule of weeping forsythia 15 parts, the raw Radix Astragali 30 parts, glossy privet
Son 10 parts, selfheal 30 parts, play both sides of the street 15 parts, the red sage root 15 parts, cornu cerve degelatinatum 15 parts and Gorgon fruit 15
Part.
According to the exemplary embodiment of the present invention, medicament can be decoction.
According to the exemplary embodiment of the present invention, Chinese medicine material can be by radix bupleuri 9 parts-10 parts, moutan bark
10 parts-15 parts, spina gleditsiae 9 parts-10 parts, field pennycress 10 parts-20 parts, the capsule of weeping forsythia 10 parts-20 parts, raw Huang
Stilbene 25 parts-35 parts, the fruit of glossy privet 5 parts-15 parts, selfheal 9 parts-30 parts, play both sides of the street 5 parts-15 parts,
The red sage root 10 parts-20 parts, cornu cerve degelatinatum 10 parts-20 parts and 10 parts-20 parts compositions of Gorgon fruit.
According to the exemplary embodiment of the present invention, Chinese medicine material can by radix bupleuri 10 parts, moutan bark 10 parts,
Spina gleditsiae 10 parts, field pennycress 15 parts, the capsule of weeping forsythia 15 parts, the raw Radix Astragali 30 parts, the fruit of glossy privet 10 parts, summer are withered
Grass 20 parts, play both sides of the street 15 parts, the red sage root 15 parts, cornu cerve degelatinatum 15 parts and Gorgon fruit 15 parts composition.
According to the exemplary embodiment of the present invention, Chinese medicine material can by radix bupleuri 10 parts, moutan bark 12 parts,
Spina gleditsiae 10 parts, field pennycress 15 parts, the capsule of weeping forsythia 15 parts, the raw Radix Astragali 30 parts, the fruit of glossy privet 10 parts, summer are withered
Grass 30 parts, play both sides of the street 15 parts, the red sage root 15 parts, cornu cerve degelatinatum 15 parts and Gorgon fruit 15 parts composition.
According to another aspect of the invention, it is provided that a kind of application for treating plasma cell mastitis, should
Application is obtained by following method: put in decocting container by Chinese medicine material, and adds in decocting container
Water；After decocting the scheduled time, filter, obtain the dregs of a decoction, thus obtain for treating plasma cell mastitis
Application, wherein, Chinese medicine material includes by weight: radix bupleuri 9 parts-10 parts, moutan bark 10 part-15
Part, spina gleditsiae 9 parts-10 parts, field pennycress 10 parts-20 parts, the capsule of weeping forsythia 10 parts-20 parts, the raw Radix Astragali 25 parts
-35 parts, the fruit of glossy privet 5 parts-15 parts, selfheal 9 parts-30 parts, play both sides of the street 5 parts-15 parts, the red sage root 10
Part-20 parts, cornu cerve degelatinatum 10 parts-20 parts and Gorgon fruit 10 parts-20 parts.
According to the exemplary embodiment of the present invention, Chinese medicine material can be by radix bupleuri 9 parts-10 parts, moutan bark
10 parts-15 parts, spina gleditsiae 9 parts-10 parts, field pennycress 10 parts-20 parts, the capsule of weeping forsythia 10 parts-20 parts, raw Huang
Stilbene 25 parts-35 parts, the fruit of glossy privet 5 parts-15 parts, selfheal 9 parts-30 parts, play both sides of the street 5 parts-15 parts,
The red sage root 10 parts-20 parts, cornu cerve degelatinatum 10 parts-20 parts and 10 parts-20 parts compositions of Gorgon fruit.
According to another aspect of the invention, it is provided that a kind of drug regimen for treating plasma cell mastitis
The preparation method of thing, this preparation method includes putting in decocting container Chinese medicine material, and to decocting container
Middle addition water；After decocting the scheduled time, filtering, prepare pharmaceutical composition, wherein, Chinese medicine material is by weight
Amount part includes: radix bupleuri 9 parts-10 parts, moutan bark 10 parts-15 parts, spina gleditsiae 9 parts-10 parts, field pennycress
10 parts-20 parts, the capsule of weeping forsythia 10 parts-20 parts, the raw Radix Astragali 25 parts-35 parts, the fruit of glossy privet 5 parts-15 parts, summer withered
Grass 9 parts-30 parts, play both sides of the street 5 parts-15 parts, the red sage root 10 parts-20 parts, cornu cerve degelatinatum 10 parts-20 parts and Gorgon euryale
Real 10 parts-20 parts.
According to the exemplary embodiment of the present invention, in the step decocting the scheduled time, can be by appearance of boiling medicine
After device big fire is boiled, little fire decocts 30 minutes.
According to the present invention for treating the Chinese medicine material composition of plasma cell mastitis, pharmaceutical composition
Have play strengthening spleen, tonifying kidney altogether, dredging collateral disappears the effect of carbuncle dissipating bind, and be capable of into purulence person and promote into purulence,
Person promotes ulceration to become purulence, and ulceration person promotes healing, fundamentally improves the quality of life of patient.This
Outward, according to the pharmaceutical composition of the present invention with without obvious toxic-side effects.Additionally, by the medicine group of the present invention
The application of compound and the present invention is with the use of can preferably treat plasma cell mastitis illness.
Detailed description of the invention
Will be described in now the present invention for treat plasma cell mastitis Chinese medicine material composition,
Pharmaceutical composition and application and it is for treating the preparation side of the pharmaceutical composition of plasma cell mastitis
Method.
Present inventor combines clinical disease performance on the basic pathogenesis of deficient vital QI leading to lingering of pathogen, sums up spleen
Deficiency of the kidney is empty, have the basic card type feature of heat poison concurrently, and then proposition tonifying speen and tonifying kidney, detoxicating and resolving a mass are main sight
Point.Spleen governing muscles, invigorating the spleen then granulation obtains raw, fistula mouth and must heal；Kidney qi metaplasia menses, menses excites punching to appoint
Logical Sheng, kidney tonifying makes punching appoint conditioning, mechanism of qi unobstructed, and fester draws；Detoxifying, thermal imagery must go, and dissipating bind then swells
Block must disappear.Thus, the present invention proposes a kind of whole process with pure Chinese medicine to treat the use of plasma cell mastitis
Chinese medicine material composition, pharmaceutical composition and application in treatment plasma cell mastitis.
Radix bupleuri, male is included for the Chinese medicine material composition treating plasma cell mastitis according to the present invention
The root bark of tree peony, spina gleditsiae, field pennycress, the capsule of weeping forsythia, the raw Radix Astragali, the fruit of glossy privet, selfheal, play both sides of the street, the red sage root,
Cornu cerve degelatinatum and Gorgon fruit.
The consumption of radix bupleuri (Radix Bupleuri) in the range of 9 weight portion-10 weight portions, such as bavin
Consumption recklessly can be 10 weight portions.Radix bupleuri plays soothing the liver effect in the pharmaceutical composition of the present invention.
The consumption of moutan bark (Cortex Moutan) is in the range of 10 weight portion-15 weight portions, such as
The consumption of moutan bark can be 10 weight portions.It is cool that moutan bark plays heat-clearing in the pharmaceutical composition of the present invention
Blood, effect promoting blood circulation and removing blood stasis.
The consumption of spina gleditsiae (Spina Gleditsiae) is in the range of 9 weight portion-10 weight portions, such as,
The consumption of spina gleditsiae can be 10 weight portions.Spina gleditsiae plays detumescence support in the pharmaceutical composition of the present invention
Poison, the effect of apocenosis.
The consumption of field pennycress (Patrinia) in the range of 10 weight portion-20 weight portions, such as field pennycress
Consumption can be 15 weight portions.Field pennycress play in the pharmaceutical composition of the present invention clearing heat and detoxicating, disappear
Carbuncle apocenosis, the effect of stasis-dispelling and pain-killing.
The consumption of the capsule of weeping forsythia (Fructus Forsythiae) is in the range of 10 weight portion-20 weight portions, such as
The consumption of the capsule of weeping forsythia can be 15 weight portions.The capsule of weeping forsythia play in the pharmaceutical composition of the present invention clearing heat and detoxicating,
The effect of dispersing swelling and dissipating binds.
The consumption of the raw Radix Astragali (Radix Astragali) is in the range of 25 weight portion-35 weight portions, such as
The consumption of the raw Radix Astragali can be 30 weight portions.It is solid that the raw Radix Astragali plays tonifying Qi in the pharmaceutical composition of the present invention
Table, pus draining and toxin expelling, the effect of expelling pus and promoting granulation.
The consumption of the fruit of glossy privet (Fructus Ligustri Lucidi) in the range of 5 weight portion-15 weight portions,
Such as, the consumption of the fruit of glossy privet can be 10 weight portions.The fruit of glossy privet plays in the pharmaceutical composition of the present invention
Nourishing liver and kidney effect.
The consumption of selfheal (Spica Prunellae) is in the range of 9 weight portion-30 weight portions.Summer is withered
Grass play in the pharmaceutical composition of the present invention relieve inflammation or internal heat, dissipating bind, the effect of detumescence.
Play both sides of the street the consumption of (Fructus Liquidambaris) in the range of 5 weight portion-15 weight portions.
Play both sides of the street in the pharmaceutical composition of the present invention, play the effect of dredging collateral.
The consumption of the red sage root (Radix Et Rhizoma Salviae Miltiorrhizae) is at 10 weight portion-20 weights
In the range of amount part, such as, the weight of the red sage root can be 15 weight portions.The red sage root is in the medicine group of the present invention
Compound plays the effect of promoting blood circulation pain relieving.
The consumption of cornu cerve degelatinatum (Cornu Cervi Degelatinatum) is at the model of 10 weight portion-20 weight portions
In enclosing, the consumption of such as cornu cerve degelatinatum can be 15 weight portions.Cornu cerve degelatinatum is in the pharmaceutical composition of the present invention
Play warming kidney and enhancing yang, the effect restraining, stopping blooding.
The consumption of Gorgon fruit (Semen Euryales) in the range of 10 weight portion-20 weight portions, such as Gorgon euryale
Real consumption can be 15 weight portions.Gorgon fruit plays supplementing the kidney to control the nocturnal, benefit in the pharmaceutical composition of the present invention
The effect of spleen antidiarrheal.
In an exemplary embodiment of the present invention, the Chinese medicine for treating plasma cell mastitis of the present invention
Feedstock composition may include that radix bupleuri 9 parts-10 parts, moutan bark 10 parts-15 parts, spina gleditsiae 9 part-10
Part, field pennycress 10 parts-20 parts, the capsule of weeping forsythia 10 parts-20 parts, the raw Radix Astragali 25 parts-35 parts, the fruit of glossy privet 5 parts
-15 parts, selfheal 9 parts-30 parts, play both sides of the street 5 parts-15 parts, the red sage root 10 parts-20 parts, cornu cerve degelatinatum 10
Part-20 parts and Gorgon fruit 10 parts-20 parts.
In an exemplary embodiment of the present invention, the Chinese medicine for treating plasma cell mastitis of the present invention
Feedstock composition may include that radix bupleuri 10 parts, moutan bark 10 parts, spina gleditsiae 10 parts, field pennycress 15
Part, the capsule of weeping forsythia 15 parts, the raw Radix Astragali 30 parts, the fruit of glossy privet 10 parts, selfheal 20 parts, play both sides of the street 15 parts,
The red sage root 15 parts, cornu cerve degelatinatum 15 parts and Gorgon fruit 15 parts.
In the another exemplary embodiment of the present invention, the present invention for treating plasma cell mastitis
Chinese medicine material composition may include that radix bupleuri 10 parts, moutan bark 12 parts, spina gleditsiae 10 parts, field pennycress
15 parts, the capsule of weeping forsythia 15 parts, the raw Radix Astragali 30 parts, the fruit of glossy privet 10 parts, selfheal 30 parts, play both sides of the street 15
Part, the red sage root 15 parts, cornu cerve degelatinatum 15 parts and Gorgon fruit 15 parts.
Is by above-mentioned Chinese medicine material according to the present invention for treating the pharmaceutical composition of plasma cell mastitis
The medicament that composition is made.In an exemplary embodiment of the present invention, medicament can be with decoction.
The pharmaceutical composition of the present invention can use the customary preparation methods of Chinese medicine to prepare.Preparation method bag
Include: above-mentioned Chinese medicine material is put in decocting container, and in decocting container, add water to not having Chinese medicine former
Material；After decocting the scheduled time, filter, prepare pharmaceutical composition.
In an exemplary embodiment of the present invention, in the step decocting the scheduled time, can be by appearance of boiling medicine
After device big fire is boiled, little fire decocts 30 minutes.
Traditional external treatment with Chinese medicine method has hydrotherapeutics and fumigating system etc..Wherein, " becoming soaked with sweat " in hydrotherapeutics is
The gauze or cotton-wool that are full of liquid are spread on affected part, and " stain " is to be soaked among liquid in affected part.Fumigating system
It is a kind of by vapotherapy, makes the method that the efficacy of a drug penetrates into tissue.The present inventor innovatively uses
The dregs of a decoction apply a hot compress to the affected part, thus are organically combined with fumigating system by hydrotherapeutics, can learn from other's strong points to offset one's weaknesses, and simply
Easy, make the efficacy of a drug go directly affected part.Thus, present applicant proposes one for treating plasma cell mastitis
Application.
The application being used for treating plasma cell mastitis of the present invention obtains by the following method: Chinese medicine is former
Material is put in decocting container, and adds water in decocting container；After decocting the scheduled time, filter, obtain
The dregs of a decoction, thus obtain the application for treating plasma cell mastitis.Wherein, Chinese medicine material and above-mentioned use
Identical in the Chinese medicine material composition for the treatment of plasma cell mastitis, therefore it will not be repeated.
In order to more effectively treat plasma cell mastitis, the pharmaceutical composition of the present invention can taken
Simultaneously by the application hot compress of the present invention in affected part.Specifically, can be by each for the pharmaceutical composition of the present invention
Within after Yu Zao, dinner 1 hour, take；And the dregs of a decoction (that is, application) stayed after boiling medicine directly hot compress
(comprising at ulceration and at redness, wherein ulceration is sentenced with the direct hot compress of the dregs of a decoction or uses mono layer gauze bag in affected part
Wrap up in rear hot compress), each 30 minutes, every day 2 times, application external application scope can be more than disease damage scope, thick
Spend and be as the criterion covering disease damage color.
It has been investigated that, take the pharmaceutical composition of the present invention and coordinate application hot compress, during treatment without
Incision and drainage, debridement, resection operation.All patients all obtains healing, i.e. pain and lump through treatment
Disappearance, otch or fistula healing, color ultrasound examination confirms local echo without exception or dilating catheter；Averagely control
More the time is 86.4 (30-158) sky.Additionally, have no during Zhi Liao that bad reaction occurs.Therefore, originally
Pharmaceutical composition and the application of invention have outstanding efficacy and saferry.
Play invigorating the spleen altogether mend according to having for the pharmaceutical composition treating plasma cell mastitis of the present invention
Kidney, dredging collateral disappear the effect of carbuncle dissipating bind, and are capable of into purulence person and promote into purulence, and person promotes to have become purulence
Ulceration, ulceration person promote healing, fundamentally improve the quality of life of patient.Additionally, according to this
Bright pharmaceutical composition is without obvious toxic-side effects.Additionally, by the pharmaceutical composition of the present invention with the present invention's
Application is with the use of can preferably treat plasma cell mastitis illness.
Below by with specific embodiment describe the present invention be used for treat plasma cell mastitis
Pharmaceutical composition, application and preparation method.
Embodiment 1
Preparation: by 9g radix bupleuri, 10g moutan bark, 9g spina gleditsiae, 10g field pennycress, the 10g capsule of weeping forsythia, 25g
The raw Radix Astragali, the 5g fruit of glossy privet, 9g selfheal, 5g play both sides of the street, the 10g red sage root, 10g cornu cerve degelatinatum and 10g Gorgon euryale
Joining in decocting container in fact, added water to not above-mentioned Chinese medicine material afterwards, after big fire is boiled, little fire is decocted
Boil 30 minutes, decoct to 200ml every time, filter, obtain decoction (that is, pharmaceutical composition) and the dregs of a decoction are (i.e.,
Application).
Decoct for every dose two and respectively within 1 hour, take after morning, dinner.In order to show the pharmaceutical composition pair of the present invention
The result for the treatment of of plasma cell mastitis, has investigated 30 example thick liquid cells of the pharmaceutical composition using the present invention
Property mastitis patient, result shows, all patients the most all obtain healing, none example perform the operation, the course for the treatment of
Average out to 148 days.Additionally, the pharmaceutical composition non-evident effect of the present invention, it is worth thin at treatment slurry
Born of the same parents' property mastitis aspect is promoted.
Embodiment 2
Preparation: by 9.5g radix bupleuri, 11g moutan bark, 9.5g spina gleditsiae, 20g field pennycress, the 20g capsule of weeping forsythia,
The raw Radix Astragali of 30g, the 14g fruit of glossy privet, 28g selfheal, 15g play both sides of the street, the 20g red sage root, 15g cornu cerve degelatinatum and
20g Gorgon fruit joins in decocting container, adds water to not above-mentioned Chinese medicine material afterwards, after big fire is boiled,
Little fire decocts 30 minutes, decocts to 200ml every time, filters, obtain decoction (that is, pharmaceutical composition) and
The dregs of a decoction (that is, application).
Decoct for every dose two and respectively within 1 hour, take after morning, dinner.In order to show the pharmaceutical composition pair of the present invention
The result for the treatment of of plasma cell mastitis, has investigated 30 example thick liquid cells of the pharmaceutical composition using the present invention
Property mastitis patient, result shows, all patients the most all obtain healing, none example perform the operation, the course for the treatment of
Average out to 133 days.Additionally, the pharmaceutical composition non-evident effect of the present invention, it is worth thin at treatment slurry
Born of the same parents' property mastitis aspect is promoted.
Embodiment 3
Preparation: by 10g radix bupleuri, 11g moutan bark, 9g spina gleditsiae, 16g field pennycress, the 17g capsule of weeping forsythia, 35g
The raw Radix Astragali, the 9g fruit of glossy privet, 15g selfheal, 10g play both sides of the street, the 13g red sage root, 14g cornu cerve degelatinatum and 15g
Gorgon fruit joins in decocting container, adds water to not above-mentioned Chinese medicine material afterwards, after big fire is boiled, and little fire
Decoct 30 minutes, decoct to 200ml every time, filter, obtain decoction (that is, pharmaceutical composition) and the dregs of a decoction
(that is, application).
Decoct for every dose two and respectively within 1 hour, take after morning, dinner.In order to show the pharmaceutical composition pair of the present invention
The result for the treatment of of plasma cell mastitis, has investigated 30 example thick liquid cells of the pharmaceutical composition using the present invention
Property mastitis patient, result shows, all patients the most all obtain healing, none example perform the operation, the course for the treatment of
Average out to 135 days.Additionally, the pharmaceutical composition non-evident effect of the present invention, it is worth thin at treatment slurry
Born of the same parents' property mastitis aspect is promoted.
Embodiment 4
Preparation: by 10g radix bupleuri, 10g moutan bark, 10g spina gleditsiae, 15g field pennycress, the 15g capsule of weeping forsythia,
The raw Radix Astragali of 30g, the 10g fruit of glossy privet, 20g selfheal, 15g play both sides of the street, the 15g red sage root, 15g cornu cerve degelatinatum and
15g Gorgon fruit joins in decocting container, adds water to not above-mentioned Chinese medicine material afterwards, after big fire is boiled,
Little fire decocts 30 minutes, decocts to 200ml every time, filters, obtain decoction (that is, pharmaceutical composition) and
The dregs of a decoction (that is, application).
Administering mode: decoct respectively 1 hour clothes after morning, dinner for every dose two；The dregs of a decoction are left and taken, with 40 after boiling medicine
The dregs of a decoction about DEG C directly contact affected part hot compress, and (comprising at ulceration and at redness, wherein ulceration sentences medication
The direct hot compress of slag or with mono layer gauze wrap up after hot compress), each 30 minutes, every day 2 times.Dregs of a decoction external application
Scope is more than disease damage scope, and thickness is as the criterion to cover disease damage color.
In order to show pharmaceutical composition and the application result for the treatment of to plasma cell mastitis of the present invention, examine
Having examined pharmaceutical composition and the 30 example plasma cell mastitis patients of application using the present invention, result shows
Showing, all patients the most all obtain healing, none example perform the operation, the course for the treatment of average out to 125.8 days, it is seen then that
While taking the pharmaceutical composition of the present invention, the application of the external application present invention can reach preferably to treat effect
Really.Additionally, the pharmaceutical composition non-evident effect of the present invention, it is worth in treatment plasma cell mastitis
Aspect is promoted.
Embodiment 5
Preparation: by 10g radix bupleuri, 12g moutan bark, 10g spina gleditsiae, 15g field pennycress, the 15g capsule of weeping forsythia,
The raw Radix Astragali of 30g, the 10g fruit of glossy privet, 30g selfheal, 15g play both sides of the street, the 15g red sage root, 15g cornu cerve degelatinatum and
15g Gorgon fruit joins in decocting container, adds water to not above-mentioned Chinese medicine material afterwards, after big fire is boiled,
Little fire decocts 30 minutes, decocts to 200ml every time, filters, obtain decoction (that is, pharmaceutical composition) and
The dregs of a decoction (that is, application).
Administering mode: decoct respectively 1 hour clothes after morning, dinner for every dose two；The dregs of a decoction are left and taken, with 40 after boiling medicine
The dregs of a decoction about DEG C directly contact affected part hot compress, and (comprising at ulceration and at redness, wherein ulceration sentences medication
The direct hot compress of slag or with mono layer gauze wrap up after hot compress), each 30 minutes, every day 2 times.Dregs of a decoction external application
Scope is more than disease damage scope, and thickness is as the criterion to cover disease damage color.
In order to show pharmaceutical composition and the application result for the treatment of to plasma cell mastitis of the present invention, examine
Having examined pharmaceutical composition and the 30 example plasma cell mastitis patients of application using the present invention, result shows
Showing, all patients the most all obtain healing, none example perform the operation, the course for the treatment of average out to 120 days, it is seen then that
While taking the pharmaceutical composition of the present invention, the application of the external application present invention can reach preferably to treat effect
Really.Additionally, the pharmaceutical composition non-evident effect of the present invention, it is worth in treatment plasma cell mastitis
Aspect is promoted.
In sum, the pharmaceutical composition being used for treating plasma cell mastitis according to the present invention can be real
Person promotes into purulence now not to become purulence, and person promotes ulceration to become purulence, and ulceration person promotes healing, fundamentally carries
The quality of life of high patient.
Additionally, according to the pharmaceutical composition of the present invention without obvious toxic-side effects.
Additionally, by the application of the pharmaceutical composition of the present invention and the present invention with the use of can preferably treat
Plasma cell mastitis illness.
The preferred embodiment of the present invention described in detail above, but, the present invention is not limited to above-mentioned reality
Execute the detail in mode.In the technology concept of the present invention, can be to the technical side of the present invention
Case carries out multiple modification and combination, and these modification and combination belong to protection scope of the present invention.
Claims (10)
1. the pharmaceutical composition being used for treating plasma cell mastitis, it is characterised in that described medicine
The medicament that composition is made up of Chinese medicine material, described Chinese medicine material includes by weight:
Radix bupleuri 9 parts-10 parts, moutan bark 10 parts-15 parts, spina gleditsiae 9 parts-10 parts, field pennycress 10 parts
-20 parts, the capsule of weeping forsythia 10 parts-20 parts, the raw Radix Astragali 25 parts-35 parts, the fruit of glossy privet 5 parts-15 parts, selfheal 9
Parts-30 parts, play both sides of the street 5 parts-15 parts, the red sage root 10 parts-20 parts, cornu cerve degelatinatum 10 parts-20 parts and Gorgon fruit 10
Part-20 parts.
Pharmaceutical composition the most according to claim 1, it is characterised in that described Chinese medicine material is by weight
Amount part includes: radix bupleuri 10 parts, moutan bark 10 parts, spina gleditsiae 10 parts, field pennycress 15 parts, the capsule of weeping forsythia 15
Part, the raw Radix Astragali 30 parts, the fruit of glossy privet 10 parts, selfheal 20 parts, play both sides of the street 15 parts, the red sage root 15 parts,
Cornu cerve degelatinatum 15 parts and Gorgon fruit 15 parts.
Pharmaceutical composition the most according to claim 1, it is characterised in that described Chinese medicine material is by weight
Amount part includes: radix bupleuri 10 parts, moutan bark 12 parts, spina gleditsiae 10 parts, field pennycress 15 parts, the capsule of weeping forsythia 15
Part, the raw Radix Astragali 30 parts, the fruit of glossy privet 10 parts, selfheal 30 parts, play both sides of the street 15 parts, the red sage root 15 parts,
Cornu cerve degelatinatum 15 parts and Gorgon fruit 15 parts.
Pharmaceutical composition the most according to claim 1, it is characterised in that described medicament is decoction.
5. the Chinese medicine material composition being used for treating plasma cell mastitis, it is characterised in that described
Chinese medicine material composition includes by weight:
Radix bupleuri 9 parts-10 parts, moutan bark 10 parts-15 parts, spina gleditsiae 9 parts-10 parts, field pennycress 10 parts
-20 parts, the capsule of weeping forsythia 10 parts-20 parts, the raw Radix Astragali 25 parts-35 parts, the fruit of glossy privet 5 parts-15 parts, selfheal 9
Parts-30 parts, play both sides of the street 5 parts-15 parts, the red sage root 10 parts-20 parts, cornu cerve degelatinatum 10 parts-20 parts and Gorgon fruit 10
Part-20 parts.
Chinese medicine material composition the most according to claim 5, it is characterised in that described Chinese medicine material
Composition includes by weight: radix bupleuri 10 parts, moutan bark 10 parts, spina gleditsiae 10 parts, field pennycress 15
Part, the capsule of weeping forsythia 15 parts, the raw Radix Astragali 30 parts, the fruit of glossy privet 10 parts, selfheal 20 parts, play both sides of the street 15 parts,
The red sage root 15 parts, cornu cerve degelatinatum 15 parts and Gorgon fruit 15 parts.
Chinese medicine material composition the most according to claim 5, it is characterised in that: described Chinese medicine material
Composition includes by weight: radix bupleuri 10 parts, moutan bark 12 parts, spina gleditsiae 10 parts, field pennycress 15
Part, the capsule of weeping forsythia 15 parts, the raw Radix Astragali 30 parts, the fruit of glossy privet 10 parts, selfheal 30 parts, play both sides of the street 15 parts,
The red sage root 15 parts, cornu cerve degelatinatum 15 parts and Gorgon fruit 15 parts.
8. the application being used for treating plasma cell mastitis, it is characterised in that described application is by such as
Lower method obtains:
Chinese medicine material is put in decocting container, and in decocting container, adds water；
After decocting the scheduled time, filter, obtain the dregs of a decoction, thus obtain for treating plasma cell mastitis
Application,
Wherein, Chinese medicine material includes by weight: radix bupleuri 9 parts-10 parts, moutan bark 10 parts-15 parts,
Spina gleditsiae 9 parts-10 parts, field pennycress 10 parts-20 parts, the capsule of weeping forsythia 10 parts-20 parts, the raw Radix Astragali 25 part-35
Part, the fruit of glossy privet 5 parts-15 parts, selfheal 9 parts-30 parts, play both sides of the street 5 parts-15 parts, the red sage root 10 part-20
Part, cornu cerve degelatinatum 10 parts-20 parts and Gorgon fruit 10 parts-20 parts.
9. the preparation method being used for treating the pharmaceutical composition of plasma cell mastitis, it is characterised in that
Described preparation method includes:
Chinese medicine material is put in decocting container, and in decocting container, adds water；
After decocting the scheduled time, filter, prepare described pharmaceutical composition,
Wherein, Chinese medicine material includes by weight: radix bupleuri 9 parts-10 parts, moutan bark 10 parts-15 parts,
Spina gleditsiae 9 parts-10 parts, field pennycress 10 parts-20 parts, the capsule of weeping forsythia 10 parts-20 parts, the raw Radix Astragali 25 part-35
Part, the fruit of glossy privet 5 parts-15 parts, selfheal 9 parts-30 parts, play both sides of the street 5 parts-15 parts, the red sage root 10 part-20
Part, cornu cerve degelatinatum 10 parts-20 parts and Gorgon fruit 10 parts-20 parts.
Preparation method the most according to claim 9, it is characterised in that decocting the scheduled time
In step, after decocting container big fire being boiled, little fire decocts 30 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610187150.7A CN105748619B (en) | 2016-03-29 | 2016-03-29 | Medicine for treating plasma cell mastitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610187150.7A CN105748619B (en) | 2016-03-29 | 2016-03-29 | Medicine for treating plasma cell mastitis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105748619A true CN105748619A (en) | 2016-07-13 |
| CN105748619B CN105748619B (en) | 2020-02-21 |
Family
ID=56345695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610187150.7A Active CN105748619B (en) | 2016-03-29 | 2016-03-29 | Medicine for treating plasma cell mastitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105748619B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453288A (en) * | 2018-12-20 | 2019-03-12 | 中国中医科学院西苑医院 | For treating the pharmaceutical composition and Chinese medicine material composition of plasma cell mastitis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083476A (en) * | 2013-02-28 | 2013-05-08 | 董志敏 | Traditional Chinese medicine for treating acute mastitis |
| CN104524168A (en) * | 2014-12-21 | 2015-04-22 | 李洋 | Medicine for treating acute mastitis |
| CN105250528A (en) * | 2015-10-19 | 2016-01-20 | 青岛市中心医院 | Medicine composition for treating plasma cell mastitis and application of medicine composition |
| CN105267365A (en) * | 2014-06-30 | 2016-01-27 | 陈希 | Liver-purging and stomach-clearing decoction for treating plasma cell mastitis |
-
2016
- 2016-03-29 CN CN201610187150.7A patent/CN105748619B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083476A (en) * | 2013-02-28 | 2013-05-08 | 董志敏 | Traditional Chinese medicine for treating acute mastitis |
| CN105267365A (en) * | 2014-06-30 | 2016-01-27 | 陈希 | Liver-purging and stomach-clearing decoction for treating plasma cell mastitis |
| CN104524168A (en) * | 2014-12-21 | 2015-04-22 | 李洋 | Medicine for treating acute mastitis |
| CN105250528A (en) * | 2015-10-19 | 2016-01-20 | 青岛市中心医院 | Medicine composition for treating plasma cell mastitis and application of medicine composition |
Non-Patent Citations (1)
| Title |
|---|
| 陈建勋: ""中西医结合治疗浆细胞性乳腺炎"", 《中国药物与临床》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453288A (en) * | 2018-12-20 | 2019-03-12 | 中国中医科学院西苑医院 | For treating the pharmaceutical composition and Chinese medicine material composition of plasma cell mastitis |
| CN109453288B (en) * | 2018-12-20 | 2021-08-20 | 中国中医科学院西苑医院 | Pharmaceutical composition and traditional Chinese medicine raw material composition for treating plasma cell mastitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105748619B (en) | 2020-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101190310B (en) | Traditional Chinese medicine composition for treating mazopathy | |
| CN102552804B (en) | Chinese medicine composite for curing verruca plantaris | |
| CN104758844A (en) | Traditional Chinese medicine for treating premature ovarian failure | |
| CN109453288B (en) | Pharmaceutical composition and traditional Chinese medicine raw material composition for treating plasma cell mastitis | |
| CN105748619A (en) | Pharmaceutical composition for treating plasma cell mastitis and preparation method thereof | |
| CN102614424A (en) | Traditional Chinese medicine for treatment of edema | |
| CN104784637B (en) | A kind of Chinese medicine composition of lavipeditum treatment diabete peripheral herve pathology | |
| CN103893432B (en) | It is a kind of to treat fracture, pharmaceutical composition of soft tissue injury and preparation method thereof | |
| CN105770400A (en) | Traditional Chinese medicine composition for treating puerperal infection | |
| CN104706919A (en) | Medicament composition for treating body surface ulcers | |
| CN105125814B (en) | It is a kind of to treat chronic renal failure III, the Chinese medicine composition of IV phase | |
| CN109985120A (en) | A kind of Chinese medicine composition that treating eczema and its application | |
| CN104667172B (en) | A kind of Chinese medicine composition for treating Hashimoto thyroiditis | |
| CN115252679B (en) | Traditional Chinese medicine composition for treating ischemic cardiomyopathy and application thereof | |
| CN108478768A (en) | Menses must lead to Chinese medicine preparation | |
| CN101401905B (en) | Chinese medicinal composition for treating aplastic anemia | |
| CN101953943A (en) | Traditional Chinese medicine for treating chronic aplastic anemia | |
| CN102920818B (en) | Formula of medicine for treating burn, scald and cold injury | |
| CN102552803A (en) | Chinese medicinal formulation for relieving breast tenderness during menstruation | |
| CN1290541C (en) | Medicinal extract for tonifying kidney and enriching blood made from foetal fuzz, and its prepn. method | |
| CN1298717A (en) | Process for preparing Tibetan medicines | |
| CN106581380A (en) | External preparation capable of promoting blood circulation to remove blood stasis and preparation method of external preparation | |
| CN105125949A (en) | Chinese drug preparation for treating syndromes after cholecystotomy | |
| CN102688318B (en) | Traditional Chinese medicine composition for treating segmental vitiligo | |
| CN115607611A (en) | Traditional Chinese medicine composition for external treatment of ulcerated superficial scrofula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20191227 Address after: 100091 No. 1, Xiyuan playground, Beijing, Haidian District Applicant after: Xiyuan Hospital of China Academy of Chinese Medical Sciences Address before: 100091 Haidian District 1 Xiyuan playground, Xiyuan Hospital, Beijing 1, China Academy of traditional Chinese Medicine Applicant before: Zhang Xiaojun |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |